CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 19 enrolled
Drug / intervention
cetrizine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04175834
NCT04175834Phase 3Completed
CompareCT.gov

Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions

Providence Health & Services·interventional·Posted Nov 25, 2019·Updated Mar 4, 2024

In Brief

A Phase 3 clinical trial evaluating cetrizine and diphenhydramine for Multiple Sclerosis and Infusion Reaction. Completed, enrolled 19 participants across 1 site.

Detailed Summary

This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Infusion Reaction
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 25, 2019
Enrollment StartFeb 5, 2020
Primary CompletionMay 13, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.6 years ago

Interventions

cetrizinedrug

prophylaxis

diphenhydraminedrug

prophylaxis